222 related articles for article (PubMed ID: 16145049)
1. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer.
Chi KN; Eisenhauer E; Fazli L; Jones EC; Goldenberg SL; Powers J; Tu D; Gleave ME
J Natl Cancer Inst; 2005 Sep; 97(17):1287-96. PubMed ID: 16145049
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer.
Chi KN; Siu LL; Hirte H; Hotte SJ; Knox J; Kollmansberger C; Gleave M; Guns E; Powers J; Walsh W; Tu D; Eisenhauer E
Clin Cancer Res; 2008 Feb; 14(3):833-9. PubMed ID: 18245546
[TBL] [Abstract][Full Text] [Related]
3. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy.
Sowery RD; Hadaschik BA; So AI; Zoubeidi A; Fazli L; Hurtado-Coll A; Gleave ME
BJU Int; 2008 Aug; 102(3):389-97. PubMed ID: 18336596
[TBL] [Abstract][Full Text] [Related]
4. Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin in development for the treatment of prostate cancer.
Zielinski R; Chi KN
Future Oncol; 2012 Oct; 8(10):1239-51. PubMed ID: 23130925
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo.
So A; Sinnemann S; Huntsman D; Fazli L; Gleave M
Mol Cancer Ther; 2005 Dec; 4(12):1837-49. PubMed ID: 16373699
[TBL] [Abstract][Full Text] [Related]
6. Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer.
Gleave M; Miyake H
World J Urol; 2005 Feb; 23(1):38-46. PubMed ID: 15770517
[TBL] [Abstract][Full Text] [Related]
7. A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer.
Tolcher AW; Kuhn J; Schwartz G; Patnaik A; Hammond LA; Thompson I; Fingert H; Bushnell D; Malik S; Kreisberg J; Izbicka E; Smetzer L; Rowinsky EK
Clin Cancer Res; 2004 Aug; 10(15):5048-57. PubMed ID: 15297406
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.
Chi KN; Hotte SJ; Yu EY; Tu D; Eigl BJ; Tannock I; Saad F; North S; Powers J; Gleave ME; Eisenhauer EA
J Clin Oncol; 2010 Sep; 28(27):4247-54. PubMed ID: 20733135
[TBL] [Abstract][Full Text] [Related]
9. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy.
July LV; Akbari M; Zellweger T; Jones EC; Goldenberg SL; Gleave ME
Prostate; 2002 Feb; 50(3):179-88. PubMed ID: 11813210
[TBL] [Abstract][Full Text] [Related]
10. Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer.
Gleave ME; Miyake H; Zellweger T; Chi K; July L; Nelson C; Rennie P
Urology; 2001 Aug; 58(2 Suppl 1):39-49. PubMed ID: 11502446
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer.
Morris MJ; Tong WP; Cordon-Cardo C; Drobnjak M; Kelly WK; Slovin SF; Terry KL; Siedlecki K; Swanson P; Rafi M; DiPaola RS; Rosen N; Scher HI
Clin Cancer Res; 2002 Mar; 8(3):679-83. PubMed ID: 11895895
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2'-O-(2-methoxy)ethyl chemistry.
Zellweger T; Miyake H; Cooper S; Chi K; Conklin BS; Monia BP; Gleave ME
J Pharmacol Exp Ther; 2001 Sep; 298(3):934-40. PubMed ID: 11504787
[TBL] [Abstract][Full Text] [Related]
13. A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers.
Chi KN; Yu EY; Jacobs C; Bazov J; Kollmannsberger C; Higano CS; Mukherjee SD; Gleave ME; Stewart PS; Hotte SJ
Ann Oncol; 2016 Jun; 27(6):1116-1122. PubMed ID: 27022067
[TBL] [Abstract][Full Text] [Related]
14. Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancer.
Chi KN; Zoubeidi A; Gleave ME
Expert Opin Investig Drugs; 2008 Dec; 17(12):1955-62. PubMed ID: 19012510
[TBL] [Abstract][Full Text] [Related]
15. Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin.
Zellweger T; Chi K; Miyake H; Adomat H; Kiyama S; Skov K; Gleave ME
Clin Cancer Res; 2002 Oct; 8(10):3276-84. PubMed ID: 12374699
[TBL] [Abstract][Full Text] [Related]
16. The potential of clusterin inhibiting antisense oligodeoxynucleotide therapy for prostate cancer.
Miyake H; Hara I; Fujisawa M; Gleave ME
Expert Opin Investig Drugs; 2006 May; 15(5):507-17. PubMed ID: 16634689
[TBL] [Abstract][Full Text] [Related]
17. Impact of dosing regimen of custirsen, an antisense oligonucleotide, on safety, tolerability and cardiac repolarization in healthy subjects.
Rabinovich-Guilatt L; Elgart A; Erisson L; Willsie SK; Tessler S; Barnett-Griness O; Pande A; Spiegelstein O
Br J Clin Pharmacol; 2015 Sep; 80(3):436-45. PubMed ID: 25782535
[TBL] [Abstract][Full Text] [Related]
18. Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors.
Liu T; Liu PY; Tee AE; Haber M; Norris MD; Gleave ME; Marshall GM
Eur J Cancer; 2009 Jul; 45(10):1846-54. PubMed ID: 19342222
[TBL] [Abstract][Full Text] [Related]
19. Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcoma.
Lamoureux F; Baud'huin M; Ory B; Guiho R; Zoubeidi A; Gleave M; Heymann D; Rédini F
Oncotarget; 2014 Sep; 5(17):7805-19. PubMed ID: 25138053
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancer.
Chia S; Dent S; Ellard S; Ellis PM; Vandenberg T; Gelmon K; Powers J; Walsh W; Seymour L; Eisenhauer EA
Clin Cancer Res; 2009 Jan; 15(2):708-13. PubMed ID: 19147778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
